Background: Proven efficacious therapies are sometimes underused in patients with chronic cardiac conditions, resulting in suboptimal outcomes. We evaluated whether evidence summaries, which were either unsigned or signed by local opinion leaders, improved the quality of secondary prevention care delivered by primary care physicians of patients with coronary artery disease.
D espite the abundant evidence base for the secondary prevention of coronary artery disease, 1 many of these therapies are underused in clinical practice. [1] [2] [3] [4] These gaps between evidence and clinical reality are linked to poor outcomes for patients. 5 Improved uptake of secondary-prevention therapies would reduce cardiac morbidity and mortality. 6 However, most quality-improvement initiatives in coronary artery disease have focused on patients in hospital. Few studies have evaluated means of translating evidence into clinical practice for outpatients cared for by primary care physicians. 7 Previously, 8 we developed and tested the Local Opinion Leader Statement (Appendix 1, available at www.cmaj.ca /cgi/content/full/cmaj.090917/DC1), a quality-improvement tool consisting of a 1-page summary of evidence with explicit treatment advice about secondary prevention of coronary artery disease. This summary was endorsed by local opinion leaders and was faxed to the primary care physicians of patients with coronary artery disease. Although this fax did not lead to a significant improvement in statin prescribing, our pilot trial was small (117 patients) and enrolled patients with chronic coronary artery disease at the time they presented to their community pharmacy for medication refills. We hypothesized that this was not a "teachable moment" and that if the intervention was given at a time when the diagnosis was made, it would be more influential on the primary care physician.
Thus, we designed this trial to test the impact of the opinion leader statement if it was sent to the primary physician at the time when patients were diagnosed with coronary artery disease. In addition, because local opinion leaders are not always selfevident and conducting surveys to identify them for each condition and in each locale would be time-consuming and expensive, we also evaluated the impact of an unsigned statement.
Methods
The protocol for the Enhancing Secondary Prevention in Coronary Artery Disease (ESP-CAD) trial, including details about the primary care physician survey that we conducted to identify local opinion leaders for coronary artery disease in Edmonton and Calgary, has been published. 1 In brief, we conducted a randomized clinical trial in these cities clustered at the level of the primary care physician to avoid contamination. We tested 3 interventions: usual care, opinion leader statements and unsigned statements (Figure 1 ). Patients were screened in all 3 cardiac catheterization laboratories in Alberta (total population about 3.3 million people) between June 2005 and January 2008 to identify adult patients with coronary artery disease (≥ 50% stenosis in at least 1 coronary vessel) detected by elective cardiac catheterization. We included patients who were eligible for but not already taking a statin or who were on a suboptimal regimen (e.g., taking a low-dose statin but whose low-density lipoprotein [LDL] cholesterol levels remained elevated) ( Table 1 ). The exclusion criteria are listed in Figure 1 . Randomization (1:1:1) was performed after completion of the patient's angiogram. Patients were randomly assigned to groups by use of a computer-generated central randomization system with concealment of the randomization list. Although the primary care physicians were not blinded to the allocation status, both allocation concealment and blinding were achieved for investigators, patients, outcome assessors and analysts.
The institutional ethics review boards at the University of Alberta and the University of Calgary approved this study, and all patients provided written informed consent.
Interventions
The opinion leader statements were imprinted with the name of the participating patient, addressed directly to the patient's Note: ACE = angiotensin-converting enzyme, ARB = angiotensin-receptor blocker, LDL = low-density lipoprotein, HDL = high-density lipoprotein, SD = standard deviation. *Unless stated otherwise. †Serum creatinine data were available only for 274 patients (n = 89, 86, 99 in the opinion leader, unsigned statement and control groups, respectively). ‡A measure of the proportion of the myocardium at risk from ischemia. §Calculated for each statin individually as a percentage of the recommended dose (Canadian Cardiovascular Society guideline) and averaged across all patients taking statins. **Statin, an antiplatelet agent and an ACE inhibitor.
physician, signed by the local opinion leaders for that city, and faxed automatically by a software program that was developed by the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) for this trial. Each physician received a fax containing objective evidence of the patient's coronary artery disease (in the form of a coronary artery diagram) 9 and either a signed or unsigned statement. These faxes were sent to physicians within a few days of the angiogram. The unsigned statements were identical to the opinion leader statements in content and form but did not contain the opinion leaders' signatures. The unsigned statements were faxed to physicians in the same manner as the opinion leader statements.
Controls
Physicians of the control patients received a fax containing the coronary artery diagram for their patient (this represents an enhancement over and above usual care in our province). This ensured that the physicians of all participants received the same number of faxes, with the only difference being the content.
Outcomes
The primary outcome was improved statin management, which we defined as initiation or increased dosage of a statin within the first 6 months after cardiac catheterization. To compare dosing across statins, we calculated the mean standardized statin dose for each prescribed statin as a percentage of the target dose specified for each agent in the guidelines. 10 We also collected data about a number of secondary outcomes (Table 2 ). Medication outcomes were based on patient self-report (with cross-referencing to pharmacy records), and laboratory data and clinical outcomes were extracted from medical records. Follow-up data were collected by independent assessors blinded to the groups. The clinical events were Note: ACE = angiotensin-converting enzyme, ARB = angiotensin-receptor blocker, ED = emergency department, SD = standard deviation. *Unless otherwise stated. †Adjusted for physician-level clustering. p values for statin initiation or dose increase were from generalized estimating equations that adjusted for physician-level clustering, patient age, sex, baseline low-density lipoprotein (LDL) cholesterol, and whether the patient saw a specialist in follow-up. ‡For those on statins, calculated for each statin individually as percentage of the Canadian Cardiovascular Society guideline-recommended dose, then averaged across all patients taking statins.
§Triple therapy defined as a statin, an antiplatelet agent and an ACE inhibitor. **Of the 29 smokers in the opinion leader group, 29 smokers in the unsigned statement group and 31 smokers in the control group. † †Acute coronary syndrome, stroke or transient ischemic attack, or unplanned revascularization.
independently adjudicated by 2 blinded investigators (F.A.M. and S.R.M.) who then met to resolve discrepancies.
Statistical analysis
Statistical analyses were conducted by a statistician blinded to allocation status. Intention-to-treat analyses were carried out with patients as the unit of analysis and causal inference. We used the χ 2 test and subsequently generalized estimating equations to adjust for baseline covariables and clustering 11 to compare the attainment of our primary outcome within 6 months among patients in the control group versus those in the opinion leader statement group, the unsigned statement group and both the opinion leader and unsigned statement groups (because both are point-of-care evidence reminders). We also performed a limited number of posthoc exploratory subgroup analyses defined by the use of statins at baseline, the level of LDL at baseline and the involvement of a specialist after cardiac catheterization. Neither the ESP-CAD study protocol nor the faxed statements advocated for or against specialist involvement after catheterization, and the decision to involve a specialist was left to the discretion of the primary care physician.
We targeted a total sample size of 480 patients (160 patients per arm) to detect a 15% absolute difference in the primary outcome over control rates, with an α of 0.05 (2-sided) and 80% power.
Results

Patient characteristics
Of the 4546 patients screened, 715 were eligible, and 480 (67%) agreed to participate (Figure 1 ). These patients were drawn from 252 primary care practices. The average cluster size was 1.9 patients per practice and the intraclass correlation coefficient for statin prescribing at 6 months was 0.019. We evaluated the status of 466 patients (97%) after 6 months (2 patients were lost to follow-up, 6 withdrew consent, 3 died and 3 were excluded because of protocol violations [2 were ineligible at randomization and 1 underwent a lung transplant during follow-up]).
At baseline, there were no statistically significant differences between the groups (Table 1) . Although 66% of patients were taking a statin at baseline, the dosing was relatively low (the mean standardized dose was 32% of the guideline-recommended therapeutic dose) with no appreciable differences between the treatment arms (p = 0.87 for statin use; p = 0.84 for statin dosing).
Improvement in statin therapy
At 6 months, statin therapy had improved in all 3 study arms (Table 2) trol, none of the comparisons were statistically significant ( Figure 2) . However, the opinion leader statement was associated with a statistically significant improvement over control in the group of patients who were followed by both a specialist and a primary care physician (74% v. 57%, p = 0.04, adjusted OR 2.41, 95% CI 1.12-5.18, p = 0.02).
In the multivariable analysis, only elevated LDL cholesterol at baseline (adjusted OR 1.86, 95% CI 1.29-2.69, p = 0.001, if baseline LDL was greater than median) and seeing a specialist during follow-up (adjusted OR 1.56, 95% CI 1.05-2.33, p = 0.03) were significantly associated with improved statin therapy. About 40% (n = 196) of the patients were seen by a specialist after cardiac catheterization with no appreciable difference among the groups (73/165 patients in the opinion leader statement arm, 63/158 in the unsigned statement arm, and 60/157 in the control arm; p = 0.52).
Secondary outcomes
Although we observed improvements in all of the secondary outcomes, none except the use of β-blockers differed significantly among the trial arms ( Table 2 ). The mean fasting LDL cholesterol levels after 6 months were similar in all 3 study arms 
Interpretation
We observed substantial improvements in the quality of secondary-prevention care for patients with coronary artery disease within 6 months of elective diagnostic cardiac catheterization. Although both of our interventions led to marked improvements over control, neither achieved statistical significance, given the 50% absolute improvement in the control group.
The magnitude of improvements after cardiac catheterization in all groups was several fold larger than usually seen with quality-improvement strategies. 7 Thus, our results reinforce the importance of testing quality-improvement interventions in randomized trials 12 -an old message, but one that is sometimes forgotten in the quality-improvement literature. 13 Had we conducted our study using the popular before-after design, we would have erroneously concluded that both the opinion leader and unsigned statement were highly effective.
Despite the improvements in statin management that we observed in all 3 arms of our trial, there is still room for improvement. Six months after cardiac catheterization, only half of the participants were taking triple therapy (statin, an antiplatelet agent and an angiotensin-converting-enzyme inhibitor), and, although over 80% were taking statins, their dosages were still low relative to the doses in clinical trials. 10, 14 As a result, less than half of the participants had attained the guideline-recommended LDL targets. Thus, our inability to show a statistically significant benefit over control cannot merely be attributed to a ceiling effect.
Why were our interventions not more effective? Both the opinion leader and unsigned statements functioned as pointof-care reminders for physicians and mentioned a specific patient, contained explicit treatment recommendations and provided the underlying evidence. Although this strategy should theoretically be effective for quality improvement, the results of empiric studies have been mixed, even if multiple reminders are sent or the reminders are delivered electronically. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] However, point-of-care evidence reminders such as the ones we used have been reported to have a more substantial effect when coupled with an alerting element that "pushes" the clinician to change prescribing. [26] [27] [28] For example, we were previously able to significantly improve bisphosphonate use among patients with osteoporosis by use of faxed opinion leader statements that were identical in format to those used in this study. However, that study included patient activation to "push" the evidence reminder (i.e., study nurses recommended to patients in the intervention group that they see their physician to discuss osteoporosis therapy). 28 This mirrors the results of our earlier study which showed that activation of patients via decision aids can induce short-term improvements in the quality of care for patients with atrial fibrillation.
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Strengths and limitations
Although we conducted a cluster randomized trial with blinded outcome ascertainment, there are some limitations to our study. First and most importantly, we underestimated the magnitude of the improvement that would occur in our control patients. Although the diagnosis of coronary disease at cardiac catheterization is a "teachable moment," which would be expected to precipitate changes in management, the greater than expected improvements in our controls may be partly explained by the fact that our control patients were not "usual care" controls. The primary care physicians of our control patients received a faxed coronary artery diagram, which likely served as a point-of-care reminder even in the control arm. Indeed, the 82% use of statins and 55% use of triple therapy in our control group 6 months after catheterization were substantially higher than the 63% and 29% observed in an analysis of patients who met the ESP-CAD criteria but who were enrolled in the APPROACH study in the 2 years before launch of our study. 30 Second, we do not know whether the intervention patients' physicians saw the intervention materials nor their opinions of the content. Third, because we recorded medication use at 6 months by patient self-report (with cross-referencing with pharmacy records), we do not know the extent to which patient noncompliance may have led us to underestimate the efficacy of our intervention on the prescribing patterns of their physicians. Fourth, our study was not designed to detect differences in health outcomes; however, the secondaryprevention therapies that we measured have been shown to be efficacious in reducing cardiovascular mortality.
Although our interventions might be considered "low-tech" given the advent of electronic health records with embedded computerized decision support, it should be noted that few primary care physicians currently use electronic records with such advanced functionality. 31 Prior studies 32 have shown that the modality of delivery of evidence prompts (computer-based v. paper-based) does not influence effectiveness. Although some may argue that unimodal interventions such as ours are too weak to influence practice, it is worth noting that several studies [26] [27] [28] have shown that relatively minimalist interventions can substantially affect practice and quality of care. Indeed, multifaceted interventions are not necessarily more effective than single interventions, 33 and to feasibly improve quality for common conditions dealt with largely in the outpatient setting (such as coronary artery disease), it is necessary to develop and evaluate minimalist interventions.
Finally, unlike prior studies of point-of-care reminders endorsed by specialists or local opinion leaders, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] our inclusion of 2 intervention arms in the ESP-CAD study permits us to disentangle the effect of local opinion leaders from that of the evidence statements (i.e., to separate the messenger from the message). We observed a greater effect of evidence statements that were endorsed by local opinion leaders compared with the anonymous (but otherwise identical) unsigned statements, although the 6% absolute difference was not statistically significant.
Conclusion
Although evidence summaries endorsed by local opinion leaders led to improvements in the quality of statin management, which may have been clinically important (10% absolute difference), our study was underpowered to detect if this difference was statistically significant, given the higher than anticipated improvements in the control arm. Regardless, our results suggest that faxed evidence reminders to primary care physicians are insufficient on their own to optimize the quality of care for patients with chronic coronary artery disease in the outpatient setting. Some form of stimulus in addition to point-of-care reminders (e.g., patient activation, 28, 29 involvement of allied health professionals 34 ) appears to be needed to optimize the care, and hence outcomes, for patients. This article has been peer reviewed.
